Type I interferon in systemic autoimmune diseases

Mary K Crow*

Abstract
A significant role for IFNα in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFNα monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus. In both of those diseases, presence of the interferon signature has been associated with more significant clinical manifestations. At the same time, evidence supports an anti-inflammatory and beneficial role of IFNβ locally in the joints of patients with rheumatoid arthritis and in murine arthritis models, and many patients with multiple sclerosis show a clinical response to recombinant IFNβ. As can also be proposed for type I diabetes mellitus, type I interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmune diseases, while maintaining some capacity to control established disease – particularly at local sites of inflammation. Recent studies in both rheumatoid arthritis and multiple sclerosis suggest that quantification of type I interferon activity or target gene expression might be informative in predicting responses to distinct classes of therapeutic agents.

Type I interferon in organ-targeted autoimmune and inflammatory diseases

The hypothesis that type I interferon plays a central role in the pathogenesis of systemic lupus erythematosus (SLE) has gained growing support in recent years [1-4]. The early data from the 1970s demonstrating increased functional interferon activity in lupus patient sera have been confirmed and extended using current technologies that permit detection of the broad gene expression program induced by type I interferons [5-8]. Expression of an interferon signature – reflecting expression of often more than 100 type I interferon-inducible genes in peripheral blood mononuclear cells (PBMC) – is also seen in highly related syndromes characterized by systemic autoimmunity, including Sjögren's syndrome [9]. In addition, clinical observations from patients treated with recombinant IFNα for control of hepatitis C infection or malignancy indicate that in some individuals, possibly determined by their harboring genetic susceptibility factors that augment response to interferon, autoantibodies characteristic of SLE can develop [10,11]. Occasionally clinical features that represent at least four of the American College of Rheumatology classification criteria for diagnosis of SLE develop in those patients.

The occurrence of clinical syndromes more characteristic of inflammatory diseases distinct from SLE in patients treated with therapeutic IFNα has gained less attention. Nonetheless, numerous case reports and case series describe inflammatory arthritis, multiple sclerosis (MS) or diabetes that develops during the course of interferon therapy [12-15]. As in the case of the lupus-like syndromes, the capacity of IFNα to promote those diseases that are typically considered to have strong inflammatory components suggests that type I interferon might also play a pathogenic role in diseases such as rheumatoid arthritis (RA), MS or type I diabetes mellitus (DM). The data supporting increased expression of IFNα and interferon-inducible genes in those diseases is less well developed than in the prototype systemic autoimmune disease SLE or in Sjögren's syndrome, which shares some autoantibody specificities and immune system alterations with SLE [16].

Confusing our understanding of the role of type I interferons in these other diseases that are characterized by systemic autoimmunity as well as pathology and clinical manifestations focused on an organ system (RA: diarthodial joints; MS: myelin sheath in the central nervous system; and DM: insulin-producing β cells in the pancreas) is the fact that type I interferons have been
postulated to be either potential or current therapies for those diseases based on their anti-inflammatory properties or on clinical experience that suggested some efficacy. The present review will describe data demonstrating activation of the type I interferon pathway in these inflammatory diseases that target specific organs, and will attempt to sort out the relative roles of type I interferons, particularly IFNα and IFNβ, as pathogenic mediators versus attractive therapeutic agents in those diseases.

Against the background of extensive data from patients with SLE, and more recently from murine lupus models [17], that demonstrate an association of interferon pathway activation with more severe disease and disease activity [18], the common and accepted use of recombinant IFNβ, alone or in combination with ribavirin, in patients with MS presents a conundrum [19]. If type I interferon is broadly pathogenic in systemic autoimmune diseases, why is IFNβ beneficial in patients with MS? A similar question can be asked with regard to RA, where IFNβ has been demonstrated in the synovial membranes of RA patients and in several murine models of inflammatory arthritis but is proposed to be anti-inflammatory and protective rather than pathogenic [20-23]. Possible explanations for these queries include the following: IFNα and IFNβ have distinct properties that confer distinct functional effects on gene expression and the immune system; the pathophysiology of the classic systemic autoimmune diseases is substantially distinct from the pathophysiology of the autoimmune diseases that are characterized by inflammation focused in specific organs; and the complex roles of both IFNα and IFNβ in host defense and immunoregulation allow for each of the interferons to play pathogenic and protective roles, depending on site of production or action, the disease context in which they act, or other factors (Figure 1). It is likely that each of these explanations accounts in part for the reality that type I interferon does contribute to autoimmune disease pathogenesis but can also control inflammation in some situations.

Common and distinct properties of IFNα and IFNβ

The type I interferons are encoded in series on human chromosome 9p. There are 13 functional IFNα genes, one IFNβ gene, one IFNκ gene encoding a protein that is preferentially expressed in skin, one IFNε gene that is expressed in placenta and fetal membranes, and one IFNω gene [24]. All of the protein products of the type I interferon family bind to a single heterodimeric receptor composed of IFNAR1 and IFNAR2. Consideration of a potential pathogenic or protective role for individual type I interferons, particularly IFNα and IFNβ, involves understanding the cell types that might preferentially produce these interferons, the distinct binding properties of IFNα and IFNβ for the type I interferon receptor (IFNAR), and whether these interferons engage distinct signaling pathways and activate distinct target genes.

While classic teaching holds that IFNβ is most effectively produced by fibroblasts and that IFNα is primarily produced by plasmacytoid dendritic cells, many cell types can in fact produce both interferons, particularly in the setting of a viral stimulus [25]. Differential production of one or another type I interferon in different contexts is probably in part cell-type related but also determined by the location of those cells [21,23,26,27]. IFNβ is produced by synoviocytes and keratinocytes, and in small amounts by monocyte-derived cells. IFNκ, a type I interferon that has attracted less attention than IFNβ and IFNα, is apparently predominantly made by keratinocytes, based on available data [28]. IFNβ-producing cells are located in tissue linings, and IFNβ can also be produced by stromal cells through a novel pathway that involves activation of lymphotixin-β receptors [29].

In contrast, plasmacytoid dendritic cells are located in peripheral lymphoid organs and, at least in disease settings, in organs affected by inflammation. In view of the widespread distribution and circulating nature of plasmacytoid dendritic cells, situations in which IFNα is produced expose the host to systemic type I interferon and might contribute to autoimmunity, while situations in which IFNβ is produced might result in more localized rather than systemic concentrations of the cytokine and abrogate inflammation. At least one mechanism by which local type I interferon might reduce inflammation has been suggested to be through inhibitory effects on TNF production [30,31].

The binding properties of each of the IFNα and IFNβ proteins for IFNAR1 can vary, depending on interaction of the cytokine with defined amino acids of the receptor [32]. The availability of signaling components of the Jak-Stat pathway can also impact the functional results of one of the type I interferons binding to its receptor. For example, absence of Tyk2 inhibits IFNα-mediated signaling but does not alter IFNβ-mediated signaling [33]. The downstream gene targets induced by IFNα and IFNβ appear to be highly similar, although some studies have demonstrated that IFNβ is more potent than IFNα in inducing gene expression [34]. Taken together, data comparing properties and functional effects of IFNα and IFNβ would suggest that the most important contributors to differential effects of those two type I interferons relate to the location of production (predominantly local in the case of IFNβ and systemic in the case of IFNα) and to affinity of the interaction of interferon with the receptor and its impact on proximal signaling pathways.

Rheumatoid arthritis

Recent studies of gene expression in blood and synovial membranes from RA patients suggest that certain
patients may harbor distinct gene expression patterns [35,36]. Of interest, a pathogen-response gene expression program characterized by increased expression of type I interferon-inducible genes was identified in a subgroup of RA patients who also expressed high circulating anti-cyclic citrullinated peptide antibody levels, the autoantibodies associated with more destructive RA [35,36].

A recent demonstration of an association between the interferon signature and progression to arthritis in patients with arthralgias and anti-cyclic citrullinated peptide antibodies further supports a probable pathogenic role for type I interferon in RA, perhaps based on the tendency for systemic type I interferon to promote autoantibody formation [37].

In contrast, the potential relevance of type I interferon, and more specifically IFNβ, produced locally in the joint as a protective factor in RA is suggested by in vitro studies of RA synovial membrane and experiments in murine models of inflammatory arthritis. In collagen-induced and adjuvant arthritis models, intraperitoneal or intraarticular injection of IFNβ resulted in reduction of disease activity and inhibition of cartilage and bone destruction through a significant decrease of TNF and IL-6 expression and an enhancement of IL-10 responses at the site of inflammation [20,38,39]. Type I interferon might also positively affect arthritis by inhibiting the differentiation of monocytes into osteoclasts, thereby reducing bone resorption and erosions [40].

Studies of human tissue have indicated that IFNβ is present in RA synovial membranes and reduces synovial cytocyte proliferation in vitro – observations that have led to the suggestion that IFNβ is an anti-inflammatory mediator with a protective role in RA [21-23]. Administration of recombinant IFNβ in the context of a randomized, double-blind, placebo-controlled clinical trial for treatment of patients with active RA, however, showed no treatment effect with regard to clinical or radiographic scores [41]. Since synovial tissue from the patients who received the IFNβ therapy did not show a significant difference in numbers of infiltrating myeloid cells or T cells compared with the placebo group, it is possible that the dose or timing of IFNβ administration did not deliver sufficient cytokine to the joint to demonstrate an anti-inflammatory effect.
As type I interferons, particularly IFNβ, have been associated with anti-inflammatory activities in the setting of RA, and in view of the variable expression of an interferon signature among RA patients [35,36], we postulated that expression of type I interferon might represent a positive predictor of response to TNF-antagonist therapy in RA patients, while low levels of type I interferon might identify RA patients who would be candidates for alternative therapeutic options. To investigate this hypothesis, type I interferon activity was determined in plasma samples from a previously described RA cohort [42] prior to and during the course of TNF-antagonist therapy.

We showed that RA patients collectively express increased plasma type I interferon activity relative to levels in healthy controls [43]. The most significant observation, and one that will require confirmation in larger populations, was that higher levels of type I interferon activity prior to therapy with TNF inhibitors are associated with better outcomes as defined by the European League Against Rheumatism (EULAR) RA improvement criteria [43]. In view of the data showing a protective role for IFNβ in murine models of inflammatory arthritis, we looked at which interferon was the major contributor to plasma type I interferon activity in the RA patients. Inhibition experiments using monoclonal anti-IFNα and anti-IFNβ antibodies revealed that both IFNα and IFNβ contribute to type I interferon activity in RA plasma [43]. This observation is in contrast to SLE, where anti-IFNβ antibodies have little effect on plasma type I interferon activity [44]. Moreover, a higher IFNβ/IFNα ratio prior to initiation of TNF inhibitor therapy was found to be associated with a better clinical response, pointing to IFNβ, rather than IFNα, as a key contributor to control of inflammation and predictor for a better response to TNF-antagonist therapy.

IFNβ has pleiotropic immunomodulatory actions – including decreased expression of the proinflammatory cytokines IL-1β and TNFα, and enhancement of the anti-inflammatory cytokines IL-1 receptor antagonist, IL-10, and transforming growth factor beta [45-48]. IFNβ has also been shown to mediate inhibition of MHC class II expression on activated PBMC [48], inhibition of T-cell activation [49] and decreased expression of adhesion molecules [50]. Since IL-1 receptor antagonist, an anti-inflammatory cytokine, can be induced by IFNβ, we measured IL-1 receptor antagonist levels in RA patient samples. A statistically significant association was detected between baseline IL-1 receptor antagonist levels and therapeutic outcome, pointing to an elevated plasma IL-1 receptor antagonist level as an additional predictor of good response in TNF inhibitor-treated patients [43].

Perhaps consistent with our results, a report from Sekiguchi and colleagues described variability in peripheral blood gene expression of RA patients treated with infliximab. Although not reaching statistical significance, there was a trend toward increased expression of interferon-inducible genes prior to initiation of treatment in those patients who went on to respond to therapy as determined by meeting an American College of Rheumatology 50% improvement response rate at week 22 [51]. Gene expression patterns over time were variable among responders and nonresponders and with time after initiation of therapy, with a typical decrease in interferon-inducible gene expression at the 2-week time point followed by an increase in some patients.

A recent report from Van Baarsen and colleagues described data derived from whole-blood, real-time PCR analysis of a panel of interferon-response genes in RA patients treated with infliximab [52]. That group also observed a range of baseline values and changes after initiation of therapy. Rather than comparing patients based on EULAR clinical response criteria, these investigators segregated patients into two groups based on the ratio of their interferon-inducible gene expression scores before and after 1 month of therapy. Those patients who showed an increase in type I interferon-inducible gene expression at 1 month tended to have a poor clinical response to treatment as determined at 16 weeks. Analysis of a subset of their patients identified as EULAR responders or nonresponders supported this trend. This pattern of an increase in interferon pathway activation in TNF antagonist nonresponders is consistent with our earlier study of Sjögren’s syndrome patients, in which we observed a general increase in plasma type I interferon activity at 12 weeks after start of therapy in patients treated with etanercept but not in those who received placebo [16]. No conclusion could be reached regarding the relationship of interferon activity to therapeutic response as the etanercept treatment was not efficacious in those patients. Our laboratory is currently conducting studies to determine the distinct gene expression profile induced by plasma from patients who show a clinical response to TNF inhibitors compared with those patients who do not show a good clinical response.

Taken together, the available data support a relationship between type I interferon activity or interferon-inducible gene expression and effects of TNF blockade, with at least a trend toward higher levels of type I interferon prior to therapy being associated with a clinical response, and suggest that early incremental increase in interferon-inducible gene expression compared with baseline levels might predict poor response to therapy.

While TNF inhibitors have been highly successful in improving clinical outcomes for patients with RA, some patients do not respond. Additional therapeutic approaches have been approved for patients who prove to be TNF inhibitor nonresponders – including treatment with rituximab, the B-cell-depleting monoclonal
antibody that targets B-cell CD20. Preliminary data from our collaborators suggest that in contrast to our results showing superior responses to TNF inhibitor therapy in patients with increased plasma type I interferon activity at baseline, those patients who show a superior response to anti-B-cell therapy have low levels of type I interferon at baseline [53]. While it would be clinically useful to have a biomarker that permitted selection of a therapeutic approach that would prove most effective based on measurement of type I interferon levels, it is very likely that the nature of RA, the complexity of the genetic contributors to therapeutic response, and the variability in the complement of mediators produced in each patient will not allow a simple predictive test. Nonetheless, distinct relationships of systemic type I interferon levels in patients who respond to TNF inhibitors compared with those who respond to anti-B-cell therapy should stimulate new concepts regarding mechanisms of disease pathogenesis.

**Multiple sclerosis**

The moderate efficacy of recombinant IFNβ in patients with MS suggests the obvious conclusion that type I interferon is therapeutic rather than pathogenic in that disease [19]. It should be noted, however, that the clinical development programs which led to the approval of IFNβ did not define its mechanism of action. Nor has it been clear whether IFNβ offers a benefit different from that seen after administration of IFNα. In fact, the differential effects of IFNα and IFNβ are difficult to demonstrate. In general, the gene expression programs that are induced by IFNα versus IFNβ are largely overlapping [34]. While subtle differences in the binding properties of each of the interferons to IFNAR, their common receptor, have been predicted based on analysis of their amino acid sequence and mutation studies, and there are demonstrated differences in engaging downstream signaling components by the two type I interferon subtypes, their functional impact on gene expression is quite comparable [32-34].

In light of the frequent administration of therapeutic IFNβ, it is perhaps surprising that gene expression analysis of patients with relapsing remitting multiple sclerosis (RRMS) (untreated with IFNβ) has demonstrated an interferon signature similar to the more classic signature seen in many patients with SLE [31,54,55]. Van Baarsen and colleagues were among the first to discern the typical signature reflecting type I interferon activation in whole blood in their study of 29 patients with RRMS and 25 healthy controls [54]. Along with a signature of immunoglobulin-related transcripts, one of the most prominent groups of transcripts was enriched in interferon-induced genes. The authors performed several analyses of the differentially expressed genes in their dataset in comparison with genes defined as either type I or type II (IFNγ)-inducible based on data in the literature, and concluded that type I interferon-inducible genes were increased in RRMS patients compared with control subjects whereas type II-induced genes were comparable between the two groups.

Van Baarsen and colleagues went further, however, and analyzed the gene program with a view towards predicting whether bacteria – which tend to activate the immune response through NF-κB-activating TLR2 or TLR4 pathways – or viruses – which tend to activate the immune response through TLR3, TLR7 or TLR9 pathways and utilize MyD88 – are more likely to be responsible for the gene program observed in the patients. The NF-κB program was not different between patients and controls, but the interferon-induced gene program, similar to that induced by viruses, was differentially expressed. The study also compared the pattern of overexpressed genes in the RRMS patients with those induced in macaques by smallpox infection, and found that more than 50% of the patients clustered with the virus-infected macaques. The differentially expressed genes that characterized this subset of RRMS patients corresponded to those that describe a common response pathway characterizing innate immune responses to microbes [54].

A role for type I interferon in RRMS is also supported by demonstration of IFNα, IFNβ, and MxA protein in brain lesions of patients with MS [56-58]. In acute lesions, astrocytes stained positive for IFNβ, macrophages expressed more IFNα, and endothelial cells sometimes expressed both IFNα and IFNβ. Chronic lesions were more likely to be positive for IFNα [56]. MxA, a type I interferon-inducible gene product, is present in astrocytes, in infiltrating T lymphocytes, and in endothelial cells – and the presence of nearby plasmacytoid dendritic cells suggests that the interferon is produced locally [57,58]. MXA protein in peripheral blood of RRMS patients and elevated serum levels of type I interferon are also detected [55]. Since the assays used to detect type I interferon activity in MS sera are distinct from those that have been used by others to quantify that activity in SLE patients, the relative levels cannot be compared. Based on the requirement for IFNγ priming to detect MxA protein in IFNAR-positive WISH epithelial cells cultured with MS sera, however, it seems probable that the levels are likely to be lower in most MS patients than in SLE patients with detectable interferon activity. One interpretation of the data demonstrating local type I interferon and its induced protein products in MS brain is that the interferon is providing an immunosuppressive effect [56].

The paradigm of IFNα promoting systemic autoimmunity versus IFNβ reducing local inflammatory disease as an approach to understanding the role of type I interferons might apply to patients with MS treated with
The interpretation of these results suggests a complex role for the type I interferon system in MS: consistent with the Van Baarsen and colleagues study, a subset of RRMS showed a type I interferon signature in blood in the absence of treatment, with Comabella and colleagues showing increased bioactive type I interferon in the nonresponder group – an observation confirmed in a recent report [59,60]. The Comabella and colleagues study suggests that the high interferon group, those cases that do not respond to IFNβ, has an interferon pathway that is constitutively activated but is not further activated by administration of recombinant IFNβ. As the nonresponder group obviously has poorer outcomes than the IFNβ responders, one is led to the speculation that increased production of type I interferon in MS patients contributes to disease and refractoriness to therapy. Similar to mechanisms suggested relevant to SLE, myeloid dendritic cells in the nonresponder RMS patients studied by Comabella and colleagues showed increased expression of the costimulatory molecule CD86, suggesting that those cells might be capable of effective activation of self-reactive T cells.

One interpretation of the different profiles in the IFNβ responders and nonresponders is that when presented with an innate immune stimulus (such as lipopolysaccharide), the responder monocytes engage cellular mechanisms that reduce the capacity of the cells to produce type I interferon while the cells from nonresponder patients do not ramp down that pathway. Impaired production of inhibitors of the Jak-STAT pathways activated by interferon binding to IFNAR was not demonstrated by the authors, as SOCS1, SOCS2 and PIAS1 expression was comparable between responders and nonresponders. Taken together, the data draw attention to the regulatory mechanisms that modulate innate immune responses downstream of TLRs, with TLR4 the relevant pathway in the RRMS patients.

Consideration of the demonstrated increased type I interferon bioactivity, increased expression of interferon-inducible genes, and stimulatory dendritic cell phenotype in IFNβ-treated patients who do not respond to that treatment raises the possibility that, similar to the situation in SLE, type I interferon might be a pathogenic mediator in that subset of RRMS patients and might be an appropriate therapeutic target. Additional studies that characterize this interesting nonresponder group more completely from the immunologic and serologic parameters will be of great interest. Although autoantibodies are not presumed to play as significant a pathogenic role in MS as T cells, it will be interesting to know whether the interferon high nonresponder group demonstrates higher levels of relevant autoantibodies than the interferon low responder group – as is the case in interferon high SLE patients [18]. The induction of
BAFF by IFNβ has been demonstrated in MS as in other diseases and could be a mechanism that contributes to increased humoral immunity. It will also be productive to compare T-cell responses to relevant self-antigens, such as myelin basic protein, in the IFN high group – the prediction being that self-reactive T cells will be expanded or more readily activated by antigen-presenting cells in those patients.

The somewhat counterintuitive data presented by Comabella and colleagues leave hanging the issue of how IFNβ results in a beneficial effect in those patients who do respond. One should note there is general agreement that recombinant IFNβ produces only modest responses in some patients. One prediction that could be tested using samples from the published study cohorts is that patients who go on to respond to IFNβ therapy are those with more robust TNF production. While the mechanisms that account for inhibition of TNF by type I interferon are not fully elucidated, the cytokine data do show reduction in TNF in patients who complete 18 to 24 months of IFNβ therapy, many of whom are presumably clinical responders [31]. Augmentation of IL-10 by IFNβ through an IFNγ-dependent pathway might also contribute to amelioration of disease activity [60].

There seem to be three categories of defect that are associated with the IFNβ nonresponder RRMS patients: production of interferon is high; in the setting of the in vivo stimuli that characterize MS, IFNAR1 expression and signaling through TLR4 are not reduced in the nonresponders as they are in the responders; and capacity to further activate transcription of type I interferon-inducible genes is abrogated. The latter alteration might be due to a system in overdrive in which all available transcription factors are engaged; in effect, the patient’s immune system is desensitized to further activation by IFNβ. It should be noted that extremely high-level expression of gene transcripts typically associated with inflammatory states, such as CXCL10 and PBEF1, achieves levels that are substantially higher in the responders after 3 months of IFNβ therapy [59]. This concurrence of improved clinical activity and increased expression of proinflammatory mediators, at least at the transcript level, indicates that increased proinflammatory gene expression does not necessarily translate into increased inflammation. Perhaps the extremely high expression of IL1RN (IL-1 receptor antagonist) transcripts in the treated responders provides balance that counters the proinflammatory mediators.

**Type I diabetes mellitus**

If RA is an organ-focused systemic autoimmune and inflammatory disease in which local type I interferon is primarily anti-inflammatory, DM is an organ-targeted autoimmune disease in which type I interferon’s major role, at least in murine models, is pathogenic.

Stewart and colleagues were the first to demonstrate the capacity of IFNα to promote diabetes in a mouse model [61]. They showed increased expression of MHC class II and costimulatory molecules in the pancreas and linked the induction of activated antigen-presenting cells to development of self-reactive T cells. Other investigators have confirmed the disease amplifying role of type I interferon in the nonobese diabetic murine diabetes model [62-64]. While direct data regarding type I interferon expression at the site of disease are limited in patients with DM, diabetes has been induced in those patients who have received therapeutic IFNα for hepatitis C – similar to the reports of development of lupus, inflammatory arthritis or MS [65].

In view of the abundant data from murine models of diabetes demonstrating a probable pathogenic role for type I interferon, along with the induction of diabetes in some patients receiving IFNα, Stewart has suggested that inhibition of IFNα with a specific monoclonal antibody might be beneficial [66]. An opposing view has been proposed by Brod, who has put forward the interesting concept that the three diseases reviewed – RA, MS and DM – represent IFNα deficiency states, perhaps based on inadequate response to an undefined viral infection [67]. In that view, the high level expression of type I interferon and interferon-inducible genes would reflect an active but insufficient effort of the innate immune system to control a more primary inflammatory process. With this idea in mind, Brod has conducted clinical trials in which IFNα is given in oral form to patients, with the hypothesis that the IFNα will generate immunosuppressive alterations in immune function. Brod has demonstrated in a murine model that oral IFNα administration results in increased interferon-inducible gene expression in T lymphocytes [67]. In a study of patients with recent-onset DM, a trend toward preservation of pancreatic β-cell function was observed in those who received 5,000 units of recombinant IFNα by oral route daily, but not in those who received a higher dose, compared with those who received placebo [68]. No effect of treatment was seen in terms of hemoglobin A1c levels. Additional placebo-controlled trials will be required to determine whether oral administration of low-dose IFNα has a therapeutic effect in autoimmune diseases.

**Conclusions**

In contrast to SLE – where a primary pathogenic role for IFNα in autoimmunity and disease pathogenesis is supported by data from studies of genetic polymorphisms that are associated with increased type I interferon, an interferon signature in PBMC, murine lupus studies in which IFNα accelerates disease, and preliminary data from human trials indicating a positive therapeutic response in some patients receiving anti-IFNα
monoclonal antibody – the role of IFNα is more complex in the three diseases reviewed. Some of the disease-associated gene variants that have been associated with increased IFNα production in patients with SLE, such as IRF5, Tyk2 or PTTPN22, have also shown an association with RA, MS or DM, but the associations are not as well documented in those diseases [69-73].

Data in the literature support a possible pathogenic role for type I interferon in RA, MS and DM, based on demonstration of an interferon signature in blood in RA and MS and based on data from murine models in the case of DM. At the same time, type I interferon appears to play an anti-inflammatory protective role in the joint tissue of patients with RA and in several murine models of inflammatory arthritis. Similarly, some patients with MS demonstrate a beneficial therapeutic effect of IFNβ. Of note, those who show a positive clinical response tend to be those who do not demonstrate an interferon signature prior to therapy and whose PBMC are responsive to type I interferon in vivo. In the case of both RA and MS, while systemic type I interferon might play a contributing role in induction of autoimmunity, its anti-inflammatory role might be more significant. Studies in DM are less well developed, and whether blockade of type I interferon to inhibit expansion of the autoimmune process or administration of type I interferon to reduce destruction of β cells by an inflammatory process or to inhibit replication of a putative virus would be more beneficial will require further investigation.

Abbreviations

DM, type 1 diabetes mellitus; EULAR, European League Against Rheumatism; IFN, interferon; IFNAR, type I interferon receptor; IL, interleukin; MS, multiple sclerosis; NF, nuclear factor; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; RRMS, relapsing remitting multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TLR, Toll-like receptor; TNF, tumor necrosis factor.

Competing interests

MKC has received a research grant from Novo Nordisk and has had consulting relationships with Biogen-Idec, Bristol Myers Squibb, EMD Merck Serono, Genentech/Roche, Idera, and MedImmune.

Acknowledgements

The outstanding collaboration of Dr Clio Mavragani, Dr Dan La, Dr William Stohl and Dr Kyriakos Kirou on studies of the role of type I IFN in RA and SLE is acknowledged.

This article is part of Arthritis Research & Therapy Volume 12 Supplement 1: The role of IFN alpha in autoimmune disease: The full contents of the supplement are available online at http://arthritis-research.com/supplements/1/2/S1. Publication of the supplement has been supported with funding from MedImmune, LLC.

Published: 25 August 2010

References

1. Rönnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:439-463.
2. Crow MK. Interferon-α: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 2003, 48:2396-2401.
3. Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007, 316:359-386.
4. Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am 2010, 36:173-186.
5. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:8-9.
6. Baechler EC, Batliwalla FM, Kanyipis G, Gaffney PM, Ottmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615.
7. Bennett L, Palucka AK, Arce E, Cantrell VT, Borovjak J, Banchereau J, Fiscultur V. Interferon and granuloipoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723.
8. Crow MK, Kirou KA, Wohlgenuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003, 36:481-490.
9. Emamian ES, Leonard JM, Lessard CJ, Grandits M, Kirou KA, Gaffney PM, Segal B, Rhodus NL, Moser KL. Peripheral blood gene expression profiling in Sjögren’s syndrome. Genes Immun 2009, 10:265-266.
10. Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990, 227:207-210.
11. Gota C, Calabrese L. Induction of clinical autoimmunity disease by therapeutic interferon-alpha. Autoimmun. 2003, 36:511-518.
12. Wong FS, Wen L. IFN-α can both protect against and promote the development of type 1 diabetes. Ann NY Acad Sci 2008, 1150:176-189.
13. Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract 2009, 86:e19-e21.
14. Ionescu C, Micu L, Constantinescu I, Hortopan M, Ursuciu C, Voiculescu M. Prolonged treatment with interferon alpha and peginterferon induces rheumatoid arthritis syndrome and erythema nodosum. J Gastroenterol Liver Dis 2008, 17:211-212.
15. Matsuoto T, Takabatake R. Multiple sclerosis-like disease caused by alpha interferon. Ocul Immunol Inflamm 2002, 10:299-304.
16. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillmer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in etanercept-treated Sjögren’s syndrome patients. Arthritis Rheum 2007, 56:3995-4004.
17. Lu Q, Shen N, Li XM, Chen SL. Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun 2007, 8:S90-603.
18. Kirou KA, Lee C, George S, Locaua K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503.
19. Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007, 7:227-239.
20. Adriaansen J, Kuhlman RR, van Holten J, Kaynor C, Vervoordeldonk MJ, Tak PP. Intraocular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum Gene Ther 2006, 17:585-996.
21. van Holten J, Smets TJ, Blankent P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005, 64:1780-1782.
22. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:270-274.
23. Tak PP. IFN-β in rheumatoid arthritis. Front Biosci 2004, 9:3242-3247.
24. Woelk CH, Frost SD, Richman DD, Higley PE, Kosakovsky Pond SL. Evolution of the interferon alpha gene family in eutherian mammals. Gene 2007, 397:38-50.
25. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004, 50:1861-1872.
26. Fujisawa H, Kondo S, Wang B, Shiyo GM, Sauder DN. The expression and modulation of IFN-α and IFN-β in human keratinocytes. J Interferon Cytokine Res 1997, 17:217-225.
27. Daffs S, Sutlar MS, Sæsteller KJ, Gale M Jr, Diamond MS. Induction of IFN-β and the innate antiviral response in myeloid cells occurs through an
IPS-1-dependent signal that does not require IRF-3 and IRF-7. PloS Pathog 2009, 5:e1000607.

33. LaFleur DW, Nardelli B, Tsareva T, Mathier D, Feng P, Semenuk M, Taylor K, Buerger M, Chinchilla D, Roshe V, Chen G, Ruben SM, Pitka PM, Coleman TA, Moore PA. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 2001, 276:39765-39771.

34. Schneider K, Loewendorf A, De Trez C, Fulton J, Rhode A, Shumway H, Ha S, Patterson G, Pfeffer K, Niedosposav SA, Ware CF, Benedict CA. Lymphoxygen-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. Cell Host Microbe 2008, 3:67-76.

35. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunology 2004, 102:539-550.

36. Pan M, Kalie E, Scaglione BJ, Raveche ES, Schreiber G, Langer JA. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 2009, 9:824-830.

37. Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-Navikas S. Interferon-beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis 2004, 63:43-49.

38. van Holten J, Plater-Zyberk C, Tak PP. Interferon-beta for treatment of rheumatoid arthritis? Arthritis Res 2002, 4:346-352.

39. Yong WJ, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998, 51:682-689.

40. Noronha A, Toscas A, Jensen MW. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993, 46:145-153.

41. Calabrese PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997, 49:1111-1116.

42. Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ondermi A, Yi T, Williams BR, Borden EC. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-β compared with IFN-α2a. J Interferon Cytokine Res 2003, 23:655-660.

43. van der Pouw Kraan LG, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007, 66:1008-1014.

44. van der Pouw Kraan TC, van Baarsen LG, van der Pouw Kraan TC, Bärent DL, Dijkmans BA, Tak PP, Verweij CL. Regulation of IFN response gene activity during infl ammation treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010, 12:R11.

45. Thurlings RM, Boumans MJH, Tekstra J, Blisma JW, Van Baarsen LG, Os K, Bos C, Kruit KA, Crow MK, Verweij CL, Tak PP. The type I IFN signature is a negative predictor of the clinical response to rituximab treatment in RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008, 47:780-788.

46. van Baarsen LG, Wijbrandts CA, van Baarsen LG, Baggen JM, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Bärent DL, Dijkmans BA, Tak PP, Verweij CL. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006, 7:522-531.

47. van Baarsen LG, Boissier S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008, 3:e1927.

48. Trautog U, Lebom P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988, 24:245-251.

49. Landini G, Gafà V, Senafini B, Giacomini E, Visconti A, Remoli ME, Severa M, Parmentier M, Ristori G, Salvetti M, Alosi F, Cuccia EM. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurolog 2008, 67:388-401.

50. Al-Masri AH, Heidenreich F, Walter GF. Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients. Eur J Neurol 2009, 16:717-726.

51. Comabella M, Lünenborg JD, Río Sánchez A, López C, Julia E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tartof MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.

52. Axell RC, de Jong BA, Boniface K, van der Hoort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mait R, Christakos A, Kokkowitz J, Karz L, Killestein J, Polman CH, de Waal Malefyt R, Steiman L, Raman C. IFN type 1 and 17 cells define efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010, 16:406-412.

53. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993, 260:1942-1946.

54. Vasileva G, Chen SC, Zeng M, Abbandonato S, Jensen K, Gorman D, Baroudy BM, Jiang Y, Murgolo N, Lira SA. Expression of a novel murine type I IFN in the pancreatic islets induces diabetes in mice. J Immunol 2003, 170:5748-5755.

55. Hultcrantz M, Huhn MH, Wolf M, Olsson A, Jacobson S, Williams BR, Kongsren O, Flosdorff-Tullberg M. Interferons induce an antiviral state in human pancreatic islet cells. Wrology 2007, 367:92-101.
64. Li Q, Xu B, Michie SA, Rubins KH, Schreiber RD, McDevitt HO: Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008, 105:12439-12444.
65. Yamazaki M, Sato A, Takeda T, Komatsu M: Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med 2010, 49:403-407.
66. Stewart TA: Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003, 14:139-154.
67. Brod SA: Ingested type I interferon: a potential treatment for autoimmunity. J Interferon Cytokine Res 2002, 22:1133-1166.
68. Rother KI, Brown RJ, Morales MA, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA: Effect of ingested interferon-alpha on β-cell function in children with new-onset type 1 diabetes. Diabetes Care 2009, 32:1250-1255.
69. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK: Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2481-2487.
70. Kanuki SN, Crow MK, Niewold TB: The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high IFN-α activity and low tumor necrosis factor-alpha levels in patients with lupus. Arthritis Rheum 2008, 58:2818-2823.
71. Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, Toes R, Rönnelid J, Klaeskgård L, Huzinga TW, Alm G, Syvänen AC, Rönnblom L: Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007, 56:2202-2210.
72. Kristjansdóttir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C, Gustafsdottir SM, Sigurdsson S, Lundmark A, Tienari PJ, Koivisto K, Elovaara I, Pitrilä T, Reunisani M, Peltonen L, Saarela J, Hillert J, Olsson T, Landegren U, Alcina A, Fernández O, Leyva L, Guerrero M, Lucas M, Izquierdo G, Matesanz F, Syvänen AC: Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008, 45:362-369.
73. Maziarz M, Janer M, Roach JC, Hagopian W, Palmer JP, Deutsch K, Sanjeevi CB, Kockum I, Breslow N, Lernmark A: The association between the PTPN22 1858C>T variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies. Genes Immun 2010, 11:406-415.

doi:10.1186/ar2886
Cite this article as: Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Research & Therapy 2010, 12(Suppl 1):S5.